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Abstract
Background: People living with HIV (PLHIV) in African countries are living longer due to the rollout of antiretroviral
drug therapy programs, but they are at increasing risk of non-communicable diseases (NCDs). However, there
remain many gaps in detecting and treating NCDs in African health systems, and little is known about how NCDs
are being managed among PLHIV. Developing integrated chronic care models that effectively prevent and treat
NCDs among PLHIV requires an understanding of the current patterns of care delivery and the major barriers and
facilitators to health care. We present a systematic review protocol to synthesize studies of healthcare delivery for
an important subset of NCDs, cardiovascular and metabolic diseases (CMDs), among African PLHIV.
Methods/design: We plan to search electronic databases and reference lists of relevant studies published in
African settings from January 2003 to the present. Studies will be considered if they address one or both of our
major objectives and focus on health care for one or more of six interrelated CMDs (ischemic heart disease, stroke,
heart failure, hypertension, diabetes, and hyperlipidemia) in PLHIV. Our first objective will be to estimate proportions
of CMD patients along the “cascade of care”—i.e., screened, diagnosed, aware of the diagnosis, initiated on
treatment, adherent to treatment, and with controlled disease. Our second objective will be to identify unique
barriers and facilitators to health care faced by PLHIV in African countries. For studies deemed eligible for inclusion,
we will assess study quality and risk of bias using previously published criteria. We will extract study data using
standardized instruments. We will meta-analyze quantitative data at each level of the cascade of care for each CMD
(first objective). We will use meta-synthesis techniques to understand and integrate qualitative data on health-related
behaviors (second objective).
Discussion: CMDs and other NCDs are becoming major health concerns for African PLHIV. The results of our review
will inform the development of research into chronic care models that integrate care for HIV/AIDS and CMDs among
PLHIV. Our findings will be highly relevant to health policymakers, administrators, and practitioners in African settings.
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Background
The rollout of antiretroviral drug therapy (ART) over
the past decade has reduced morbidity and mortality
and produced large gains in life expectancy for people
living with HIV (PLHIV) in African countries [1]. At the
same time, the burden of non-communicable diseases
(NCDs) in the region continues to increase, due in part
to demographic changes and in part to increased expos-
ure to “Western” dietary patterns and lifestyle-related
risk factors such as tobacco smoking and obesity [2, 3].
Consequently, NCDs are increasingly becoming a focus
of public health efforts for African PLHIV [4].
Among the major NCDs, chronic cardiovascular con-
ditions such as ischemic heart disease, stroke, and heart
failure appear to occur at higher rates among PLHIV as
compared with the general population. This excess risk
has been attributed to several factors, including inflam-
matory effects of the HIV virus, side effects of particular
ART regimens, and an increased prevalence of inter-
mediary cardiovascular and metabolic conditions like
hypertension, diabetes mellitus, and hyperlipidemia [5].
This specific rise in cardiovascular risk in African PLHIV
threatens to reverse or at least attenuate the health im-
pact of ART rollout in the region [6].
The challenges to delivering health care for NCDs like
cardiovascular disease in African countries have been ex-
tensively documented [7]. With the exception of HIV/
AIDS, most health systems remain geared towards epi-
sodic care of acute conditions rather than longitudinal
care of chronic diseases [8]. Studies have recently dem-
onstrated major gaps in detecting, treating, and control-
ling NCDs in African settings [9, 10]. At the same time,
PLHIV—who are considered a priority group for global
health systems—have not been the primary focus of this
sort of research. Nor has the management of comorbid
NCDs in PLHIV been a high priority for public health
programs. So while much continues to be written about
the steady progress on delivering ART, it is much less
clear how well (or how poorly) NCDs are being managed
in this group [11].
Effectively managing NCDs in African PLHIV will re-
quire the development, evaluation, and promulgation of
chronic care models. These models should be culturally
appropriate, feasible within resource-constrained health
systems, and responsive to the local burden of disease
[12]. Developing innovative care models depends greatly
on how and where PLHIV use health services, both for
their HIV and for other health concerns. How care is de-
livered, and the possibilities for integrating care, varies
from country to country and even within countries [13].
On the one hand, routine HIV care could be offered
alongside NCD care in general primary care settings
[14]. On the other hand, specialized HIV clinics could be
strengthened and providers trained to manage NCDs
more effectively [15]. Unfortunately, aside from case
studies, there is little evidence on what model or models
of care could most effectively integrate the management
of HIV and NCDs for PLHIV. Even less clear is the role
of other recent innovations—such as mobile screening
units, nurse—and community health worker-led care
and mobile health technologies (mHealth)—in supporting
these care delivery models [16–18].
The main challenge to improving NCD care in these
settings is to enable PLHIV, who have a chronic, life-
threatening condition, to embrace the additional com-
plex demands of long-term primary and secondary pre-
vention of NCDs [19]. Chronic care interventions seek
to promote behavior change among patients and, to a
lesser extent, providers [20]. An essential first step in de-
veloping and improving models of NCD care among Af-
rican PLHIV is to describe current patterns of NCD care
delivery in these settings. Such an assessment should
quantify rates of detection, treatment, and control of
NCDs in PLHIV. It should also explore the barriers and
facilitators that influence how PLHIV seek and receive
NCD care. The knowledge gained from this sort re-
search is a critical input to the process of designing in-
terventions that support behavior change to increase
awareness, retention in care, mediation adherence, and
ultimately self-management skills [21].
In this protocol, we outline a systematic review process
that assesses patterns of NCD care delivery among PLHIV
across African settings, focusing on a specific cluster of
NCDs we term “cardiovascular and metabolic diseases”
(CMDs). The cardiovascular conditions of interest are is-
chemic heart disease, stroke, heart failure, and hyperten-
sion, and the related metabolic conditions of interest
are diabetes mellitus and hyperlipidemia. The rationale
for focusing on healthcare delivery within this cluster of
conditions is threefold. First, CMDs arise from a com-
mon set of risk factors and are part of a common patho-
physiological process that usually results in death from
acute heart attack, stroke, or decompensated heart fail-
ure. Second, primary and secondary management of
CMDs incorporate similar medications, diagnostics, and
referral pathways. Third, each CMD has been documented
to occur at increased rates among PLHIV. We focus on
diseases rather than primordial risk factors such as obesity
and tobacco smoking because the former are managed
within the healthcare system and primarily through the
use of evidence-based drug therapies.
The objective of this systematic review is to synthesize
the literature on the delivery of care for CMD among
PLHIV in African countries. Specifically, we will as-
sess rates of diagnosis, treatment, and control of CMD
and identify the distinctive health system barriers and
facilitators to preventing and managing CMD in this
group.
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Methods/design
This protocol has been registered with the PROSPERO
International Prospective Register of Systematic Reviews
(http://www.crd.york.ac.uk/PROSPERO), registration num-
ber CRD42015029375). Where applicable, we have adhered
to the Preferred Reporting Items for Systematic review
and Meta-Analysis Protocols (PRISMA-P) checklist,
which is provided as an additional file (see Additional
file 1) [22].
Patients, objectives, and conceptual models
The aim of this review is to paint a comprehensive pic-
ture of the state of healthcare delivery for CMD both
from a “primary prevention” perspective—i.e., reducing
risk of developing ischemic heart disease, stroke, and
heart failure by managing blood pressure, glucose, and
lipids—and from a “secondary prevention” perspecti-
ve—i.e., reducing the risk of recurrent, worsening, and
fatal cardiovascular disease. Again, this review seeks to
understand CMD care within the specific context of
health services for PLHIV in the African continent, as
this is where the vast majority of PLHIV live. The ra-
tionale for restricting our analysis to this region is that
African health systems are typically much more
resource-limited, and the prevalence (clinical burden) of
HIV is much higher than other regions of the world.
Our first objective is to characterize the so-called cas-
cade of care for CMDs. The concept of the cascade of
care has been widely used in the field of HIV/AIDS to
assess gaps in delivery of ART [11]. Others have applied
the concept to hypertension care [9]. An example of a
commonly used three-tiered cascade for hypertension is
provided in Fig. 1a. In a clinical context, the first step to
addressing CMD is to identify patients at risk, screen
and diagnose them appropriately, and make them aware
of their diagnosis. The second step is to initiate pharma-
cologic therapy for specific CMDs that have been diag-
nosed. The third step is to support medication
adherence and disease control, e.g., controlling hyperten-
sion by keeping blood pressure within the therapeutic
range. We expect that quantitative clinical/epidemio-
logical studies will provide the best scientific evidence to
depict this cascade of care. Hence, the outcomes of
interest within the first objective are the proportions of
PLHIV classified at various levels in the cascade of care
for each CMD.
Our second objective is to identify key barriers and facil-
itators to the delivery of health care for CMD. Barriers
and facilitators can occur both on the patient (“demand”)
side and on the provider and health system (“supply”) side.
According to social-ecological theory and multilevel
theory [23], barriers and facilitators—and potential
interventions—occur at multiple levels, ranging from
the intrapersonal to the societal (Fig. 1b). We expect
that qualitative studies will provide the best scientific
evidence to identify these health-related behaviors,
though we will consider including quantitative studies
that incorporate closed-ended questions on barriers and
facilitators that can be numerically analyzed. Hence, the
outcomes of interest within the second objective are the
key concepts and qualitative findings from studies of
health-seeking behavior related to CMD in African
PLHIV.
Eligibility criteria
We will review all studies that provide data on the afore-
mentioned outcomes related to CMDs in studies involv-
ing PLHIV in African healthcare settings. Because this
review seeks to build evidence for chronic care interven-
tions, we will focus on studies of longitudinal outpatient
care rather than acute inpatient care.
For the first objective, we will consider studies that
quantify one or more of the following proportions: diag-
nosed, aware of disease, initiated on treatment, adherent
to medication, and with controlled disease, e.g., blood
pressure, cholesterol, or glucose. (The ischemic heart
disease, stroke, and heart failure analyses will not include
the disease control outcome, since for these conditions
Fig. 1 Conceptual frameworks for this systematic review. a A
stylized cascade of care for cardiovascular and metabolic diseases.
Adapted from Chow and colleagues [9]. b The social-ecological model
applied to healthcare-seeking behaviors. Adapted from Weiner and
colleagues [23]
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it is multifactorial and depends on the presence or ab-
sence of other comorbidities.) We will include studies
that employ one of the following designs: cross-sectional
studies, case-control studies, and retrospective or pro-
spective cohort studies. We will also consider experi-
mental studies if they report on our outcomes of interest
(either before or after the intervention); however, CMD
intervention effectiveness is outside the scope of this
review.
For the second objective, we will consider studies that
ascertain barriers and facilitators to care through inter-
views, focus groups, or surveys of patients or healthcare
providers. These barriers and facilitators may include health
behaviors and attitudes or interpersonal, organizational,
or social factors (Fig. 1b). We will include both ethno-
graphic studies and structured questionnaires of pa-
tients and providers, as these methods are the most
appropriate for eliciting health-related behaviors.
We will exclude all studies conducted in settings out-
side the African continent as well as those conducted
among children (individuals less than 15 years of age)
and pregnant women. Multi-site studies will only be in-
cluded if African data can be disaggregated. We will also
exclude studies published in languages other than Eng-
lish or Afrikaans. Conference abstracts will only be con-
sidered if they meet the eligibility criteria and provide
data of sufficient quality. We will exclude abstracts or
manuscripts that present duplicate data, and we will use
only the most recent manuscript.
Importantly, we will limit our search to reports from
January 1, 2003 to the present, because 2003 is widely
regarded as the advent of widespread ART across Africa
following from large-scale programs such as the World
Health Organization’s “three by five” initiative and the
United States President’s Emergency Plan for AIDS Re-
lief. Finally, we will exclude case reports, case series, edi-
torials, and commentaries. We will temporarily retain
narrative reviews or relevant systematic reviews in order
to check their reference lists, but we will exclude them
from the analysis.
Search strategy
Our search strategy will employ four sets of terms: (1)
terms identifying studies of one or more of the six
CMDs (hypertension, diabetes mellitus, hyperlipidemia,
ischemic heart disease, stroke, and heart failure); (2)
terms identifying studies of HIV/AIDS; (3) terms identi-
fying studies of health service delivery; and (4) filters for
African countries, languages, and publication dates. We
obtained the filter for African countries from a prior
study of techniques for filtering clinical research con-
ducted in African settings [24].
Table 1 details our search strategy for PubMed, which
will be adapted to Embase and the Cumulative Index to
Nursing and Allied Health Literature. We will also use
more general terms to hand-search the African Index
Medicus (http://indexmedicus.afro.who.int/) database.
We will contact experts in the field of HIV/AIDS and
NCDs to identify key publications and review our pre-
liminary list of included studies. Finally, we will hand-
search reference lists of all included articles.
Two reviewers (NLT and MEA) will independently
screen titles, abstracts, and full-text articles, resolving
discrepancies at each stage before proceeding to the next
stage. A third reviewer (DAW) will review discrepancies.
The Covidence software (https://www.covidence.org/)
will be used to track the review process. Decisions as to
which studies will be included in the meta-analyses will
be made by consensus among the authors and will be
guided both by statistical criteria and by the risk-of-bias
assessments as described below.
Data extraction and quality assessment
We will create a standardized data extraction form to
obtain the relevant information from all included arti-
cles, and we will pilot it on a few key quantitative and
qualitative studies. The form will be divided into (1)
basic article information (author, year, location, etc.), (2)
quality assessment (see below), (3) data for first object-
ive, and (4) data for second objective.
For the first objective, we will record which CMD(s)
was/were studied (e.g., hypertension, diabetes), which
outcome(s) was/were studied (e.g., proportion screened,
proportion with controlled disease), and numerical sum-
maries of these outcomes. We recognize that studies
may use slightly different conceptualizations or terms
for the various levels of the cascade, so we will combine
studies whose data we believe speak to the same under-
lying outcome of interest. We also recognize that different
case definitions may be used across studies (e.g., fasting
blood glucose vs. hemoglobin A1c for diabetes), so we will
combine studies using different case definitions, assuming
they speak to the same disease process. We will test these
assumptions during the meta-analysis/meta-regression
stage as described below. For the second objective, we will
record which CMD(s) was/were studied, which barriers
and facilitators to care were described, and numerical
summaries of these barriers and facilitators (if provided).
The outcomes will be elaborated further in our data ex-
traction form, and we have provided a draft of this form
as an additional file (see Additional file 2).
Two reviewers (NLT and MEA) will independently ex-
tract data from included studies, and a third reviewer
(DAW) will assist with discrepancies. We will attempt to
contact study authors in cases where the study data are
unclear or key pieces of information are missing.
We will subject quantitative studies to a risk-of-bias as-
sessment that uses design-specific criteria recommended
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by the Agency for Health-related Research and Quality
[25]. We will assess qualitative studies differently; instead
of assessing quality through the lens of “bias,” we will
grade the included qualitative studies using ten criteria
adapted from the Critical Appraisal Skills Programme
(Table 2) [26]. Risk of bias assessment and quality assess-
ment will be conducted at the study level only.
Data analysis
For the first objective, we will separately analyze esti-
mates of the proportion of PLHIV at each stage of the
cascade; i.e., (1) rates of diagnosis and of awareness, (2)
rates of treatment initiation, and (3) rates of medication
adherence and of disease control. We will conduct these
three meta-analyses separately for all six CMDs of
interest.
We will first extract raw data (counts), calculate pro-
portions and their standard errors, and produce forest
plots of each of the outcomes in order to visualize the
findings. We will assess between-study heterogeneity
using the I2 statistic, with caution taken in cases where
I2 exceeds 50 % [27]. Decisions as to which studies to
include in the meta-analyses will also incorporate the
risk-of-bias assessments.
Groups of studies with sufficient homogeneity in out-
comes data will be subjected to formal meta-analyses.
We synthesize individual estimates of each outcome
using double arcsine transformation followed by inverse
variance weighted random effects meta-analysis [28]. If
the number of studies reporting any particular outcome
is sufficiently large, we will use meta-regression models
to characterize heterogeneity in the outcomes related to
study design, country, year of publication, and variation
Table 2 Criteria used for assessment of qualitative studies
1. Research aim(s) was/were clearly stated
2. Qualitative methods are an appropriate approach to this issue
3. Study design was suitable for answering the research question
4. Recruitment strategy was appropriate for the aims of the research
5. Data collection was adequate for answering the research question
6. Relationship between researcher and participants was adequately
considered
7. Other potential ethical issues were adequately considered
8. Data analysis was of sufficient rigor
9. Findings were clearly stated
10. Research adds value to science, practice, and/or policy
Table 1 Example MEDLINE search strategy
CMD terms (Cardiovascular Diseases[MeSH] OR cardiovascular diseas*[all fields] OR cardiovascular[all fields] OR hypertens*[all fields]
OR "blood pressure"[all fields] OR "blood pressures"[all fields] OR Lipid Metabolism Disorders[MeSH] OR hypercholest*[all
fields] OR hyperlipid*[all fields] OR dyslipid*[all fields] OR ischem*[all fields] OR ischaem*[all fields] OR stroke[all fields] OR
"heart failure"[all fields] OR Diabetes Mellitus[MeSH] OR Blood Glucose[MeSH] OR hyperglycemia[all fields] OR
hyperglycemic[all fields] OR "glucose tolerance"[all fields] OR "glucose intolerance"[all fields] OR "insulin resistance"[all
fields] OR “in diabetes”[all fields] OR diabetic[all fields] OR comorbidity[all fields])
HIV/AIDS terms (HIV[MeSH] OR HIV Infections[MeSH] OR "Acquired Immunodeficiency Syndrome"[all fields] OR HIV[all fields] OR
HIV Antibodies[MeSH] OR CD4 Lymphocyte Count[MeSH] OR "CD4 count"[all fields] OR "viral load"[all fields])
Health service delivery terms (Delivery of Health Care[MeSH] OR Health Education[MeSH] OR "patient education"[all fields] OR Health Care
Facilities, Manpower, and Services[MeSH] OR Health Care Quality, Access, and Evaluation[MeSH] OR Primary Health
Care[MeSH] OR Access to Information[MeSH] OR Health Behavior[MeSH] OR "accessibility of health services"[all
fields] OR "availability of health services"[all fields] OR accessibility[all fields] OR access[all fields] OR availability[all
fields] OR utiliz*[all fields] OR Physician's Practice Patterns[MeSH] OR "physician practice patterns"[all fields] OR
Attitude of Health Personnel[MeSH] OR "physician attitudes"[all fields] OR Social Behavior[MeSH] OR
Communication[Mesh] OR barrier*[all fields] OR facilitator*[all fields] OR obstacle*[all fields] OR "patient
compliance"[all fields] OR "medication adherence"[all fields] OR "medication compliance"[all fields] OR
diagnosis[MeSH] OR screening[all fields] OR diagnosis[all fields])
Filter for African countries,
languages, and publication dates
(“Africa”[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR “Burkina Faso”[tw]
OR Burundi[tw] OR Cameroon[tw] OR “Canary Islands”[tw] OR “Cape Verde”[tw] OR “Central African Republic”[tw]
OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR “Democratic Republic of Congo”[tw] OR Djibouti[tw] OR
Egypt[tw] OR “Equatorial Guinea”[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw]
OR Guinea[tw] OR “Guinea Bissau”[tw] OR “Ivory Coast”[tw] OR “Cote d’Ivoire”[tw] OR Jamahiriya[tw] OR Kenya[tw]
OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libia[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR
Mauritania[tw] OR Mauritius[tw] OR Mayote[tw] OR Morocco[tw] OR Mozambique[tw] OR Mocambique[tw] OR
Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR “Sao Tome”[tw] OR
Senegal[tw] OR Seychelles[tw] OR “Sierra Leone”[tw] OR Somalia[tw] OR “South Africa”[tw] OR “St Helena”[tw] OR
Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR “Western Sahara”[tw]
OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR “Central Africa”[tw] OR “Central African”[tw] OR “West Africa”[tw]
OR “West African”[tw] OR “Western Africa”[tw] OR “Western African”[tw] OR “East Africa”[tw] OR “East African”[tw]
OR “Eastern Africa”[tw] OR “Eastern African”[tw] OR “North Africa”[tw] OR “North African”[tw] OR “Northern Africa”[tw]
OR “Northern African”[tw] OR “South African”[tw] OR “Southern Africa”[tw] OR “Southern African”[tw] OR “sub Saharan
Africa”[tw] OR “sub Saharan African”[tw] OR “subSaharan Africa”[tw] OR “subSaharan African”[tw]) NOT (“guinea pig”[tw]
OR “guinea pigs”[tw] OR “aspergillus niger”[tw]) AND (english[la] OR afrikaans[la]) AND (2003[pdat] : 3000[pdat])
*refers to a "wildcard" character in PubMed
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in case definition. If the data are limited or cannot be
pooled because of substantial heterogeneity, we will
present the findings in narrative form.
In the final stage of analysis for the first objective, we
will consider the potential for meta-bias. The design of the
studies in which we are interested is observational rather
than experimental, and we will be synthesizing descriptive
statistics rather than effect sizes. Hence, the most relevant
form of meta-bias for our review will be publication bias.
To assess the potential for publication bias, we will pro-
duce funnel plots of included studies, looking for evidence
of asymmetry. We will, however, use this technique with
caution when assessing meta-bias in outcomes based on a
small number of studies [29].
For the second objective, we will deal with quantitative
studies (surveys) and qualitative (ethnographic) studies
separately. Studies reporting numerical estimates of
barriers and facilitators will be meta-analyzed using
the same methods employed for the first objective. We
will assess qualitative studies using a meta-synthesis
approach. Whereas the aim of quantitative meta-
analysis is to reduce the findings of multiple studies to
a series of pooled summary statistics (effect sizes), the
aim of qualitative meta-synthesis is to compare across
individual studies to generate new insights and areas of
inquiry [30].
We will begin our synthesis by recording (coding) all
the key concepts—i.e., barriers and facilitators and their
determinants—in each study, classifying them according
to whether they are primarily on the “supply” or “de-
mand” side and at which level(s) of the social-ecological
model (Fig. 1b) they apply. We will then apply the recip-
rocal translation method to compare and contrast the
concepts across pairs of studies. This method will imple-
ment a common set of (second-order) metaphors and
concepts that will be refined throughout the data synthe-
sis process [31].
We will report our findings in two ways. First, second-
order metaphors and concepts will be reported in a
series of data visualization matrices [32]. Second, the
synthesized data will be developed into a substantive
theory of CMD care-seeking behaviors (and their deter-
minants) among African PLHIV. At the same time, we
will be careful not to overgeneralize our findings across
settings or coerce heterogeneous phenomena into an
overly homogeneous theory [30].
Presenting and reporting of results
We will make use of flow diagrams to summarize the
study selection process and detail the reasons for exclud-
ing studies, following the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) state-
ment throughout. As stated above, we will present quan-
titative findings in forest plots and qualitative findings in
data display matrices. Our results and conclusions will
focus on four domains:
1. Summarizing the major gaps and “drop-offs” in
the CMD cascades across diseases and countries
2. Characterizing the most frequent barriers and
facilitators encountered across settings, including
how they may explain the cascades
3. Identifying critical knowledge gaps, e.g., absence of
studies on particular diseases or outcomes
4. Providing recommendations for future reporting
We will publish our full search strategy and our
final data extraction form along with the review as
supplementary documents that can be used by re-
searchers who wish to update this review as more
studies are conducted.
Discussion
The introduction of a successful health service delivery
model to establish ART treatment in resource-scarce
African settings has transformed HIV/AIDS into a chronic
disease. In many cases, models of HIV/AIDS care resem-
ble longitudinal care models for other chronic diseases,
though many HIV/AIDS programs remain “vertical” ra-
ther than integrated within the health system in general or
primary healthcare facilities in particular [33]. Some have
argued, controversially, that current models of HIV/AIDS
care have the potential to strengthen health systems and
improve care for other common chronic diseases in devel-
oping countries [8].
However, the notion of providing “integrated care”
for PLHIV—particularly in settings with large vertical
HIV/AIDS programs—is distinct from the notion of le-
veraging HIV/AIDS infrastructure to strengthen pri-
mary care for other common diseases (such as NCDs)
that have an impact on the general (HIV-negative)
population [14, 34]. We propose that the design of
current HIV/AIDS programs results in most PLHIV
having a very different healthcare experience than the
general population, including lower cost of care and
higher perceived quality of care as compared to other
diseases [35].
On the other hand, PLHIV are not immune either to
diet and lifestyle risks or low awareness of the conse-
quences of untreated blood pressure, glucose, and chol-
esterol [36, 37]. “Treatment overload” from multiple
chronic diseases has also been reported among PLHIV
with hypertension and diabetes [38]. Similarly, HIV/
AIDS healthcare providers are not immune to the
supply-side constraints to NCD care such as insuffi-
cient stocks of drugs and diagnostics, inadequate
medical records systems, and limited medical education
around chronic disease management [6]. Hence, in
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order to design chronic care models that support the
special needs and concerns of PLHIV in Africa, specific
research is needed on how NCD care is currently being
delivered for this group.
Our review will be most relevant for developing
country health systems managers and researchers. It
will provide comparative data on how well a specific
and important subset of NCDs—cardiovascular and
metabolic conditions—is currently being managed in
PLHIV. It will also provide insight into what sorts of
patient, provider, and social behaviors need to be tar-
geted by innovative care delivery models. In keeping
with these anticipated uses and the expected growth in
the HIV-NCD literature over time, we plan to update
this review every 3 to 5 years as additional studies are
published.
Finally, our review is not without significant limita-
tions. First, we have focused on a narrow and inter-
related set of cardiovascular and metabolic conditions.
Yet comprehensive integrated care programs for
PLHIV will also need to evaluate other conditions such
as mental health and cancer, which interface with CMD
care in many ways [39, 40]. We chose not to review
studies on all NCDs, because such a review would be
extremely broad and unmanageable. Second, we have
reduced the study of healthcare delivery to two
domains—the cascade of care and barriers and facilita-
tors to care—but in reality, the study of health systems
is more complex, and our framework excludes some as-
pects of health systems such as governance, financing,
and health information systems, all of which have indir-
ect influences on individual patient care [41]. Finally,
by limiting our review to African countries, we will
limit the opportunity to compare CMD and HIV/AIDS
in the African region to other regions, such as high-
income countries where more has been written on the
topic [38, 42].
Despite the limitations above, this review will provide
timely information on a topic of immediate public
health importance in the African region. The most cost-
effective approaches to CMD in developing countries
focus on prevention and early detection of high-risk in-
dividuals [43]. Yet the gap between scientific knowledge
and clinical practice is large, and the consequence of
this gap is that mortality from cardiovascular disease in
low-income settings is unacceptably high [44]. This re-
view will identify areas for further health systems and
implementation science research, inform the design of
care delivery models for PLHIV, and build on the health
gains that are already being achieved by ART programs.
It will also provide insights on how to integrate health
services to include PLHIV in settings where HIV/AIDS
care can feasibly be delivered in general primary care
settings.
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